AFC-HD AMS Life Science Co., Ltd. (TYO:2927)
Japan · Delayed Price · Currency is JPY 863.00
-3.00 (-0.35%)
Apr 24, 2026, 3:30 PM JST
AFC-HD AMS Life Science Income Statement
Financials in millions JPY. Fiscal year is September - August.
Millions JPY. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
| 32,887 | 32,655 | 30,185 | 25,579 | 22,997 | 22,368 | |
Revenue Growth (YoY) | 1.95% | 8.18% | 18.01% | 11.23% | 2.81% | 41.40% |
Cost of Revenue | 21,399 | 21,394 | 19,694 | 16,256 | 14,418 | 15,503 |
Gross Profit | 11,488 | 11,261 | 10,491 | 9,323 | 8,579 | 6,865 |
Selling, General & Admin | 8,799 | 8,529 | 8,349 | 7,526 | 7,415 | 4,580 |
Amortization of Goodwill & Intangibles | 291 | 291 | 222 | 160 | 152 | 38 |
Other Operating Expenses | 32 | 32 | - | - | - | 1 |
Operating Expenses | 9,121 | 8,851 | 8,575 | 7,686 | 7,567 | 4,619 |
Operating Income | 2,367 | 2,410 | 1,916 | 1,637 | 1,012 | 2,246 |
Interest Expense | -230 | -201 | -101 | -57 | -57 | -50 |
Interest & Investment Income | 27 | 24 | 10 | 16 | 16 | 15 |
Other Non Operating Income (Expenses) | 53 | 129 | 11 | 21 | 356 | -46 |
EBT Excluding Unusual Items | 2,217 | 2,362 | 1,836 | 1,617 | 1,327 | 2,165 |
Gain (Loss) on Sale of Investments | 19 | 12 | 69 | 36 | 11 | -4 |
Gain (Loss) on Sale of Assets | 5 | -2 | 38 | - | - | - |
Asset Writedown | -425 | -423 | -15 | -31 | -88 | -3 |
Other Unusual Items | 215 | 251 | -17 | -77 | -16 | -1 |
Pretax Income | 2,031 | 2,200 | 1,911 | 1,545 | 1,234 | 2,157 |
Income Tax Expense | 684 | 732 | 665 | 439 | 497 | 662 |
Earnings From Continuing Operations | 1,347 | 1,468 | 1,246 | 1,106 | 737 | 1,495 |
Minority Interest in Earnings | 21 | -20 | 6 | -4 | -2 | - |
Net Income | 1,368 | 1,448 | 1,252 | 1,102 | 735 | 1,495 |
Net Income to Common | 1,368 | 1,448 | 1,252 | 1,102 | 735 | 1,495 |
Net Income Growth | -8.31% | 15.65% | 13.61% | 49.93% | -50.84% | 121.15% |
Shares Outstanding (Basic) | 14 | 14 | 14 | 14 | 14 | 14 |
Shares Outstanding (Diluted) | 14 | 14 | 14 | 14 | 14 | 14 |
Shares Change (YoY) | 1.01% | 0.12% | -0.01% | -0.47% | 0.36% | 0.04% |
EPS (Basic) | 96.23 | 102.94 | 89.19 | 78.47 | 52.31 | 107.08 |
EPS (Diluted) | 96.23 | 102.94 | 89.11 | 78.46 | 52.08 | 106.30 |
EPS Growth | -9.22% | 15.52% | 13.57% | 50.65% | -51.01% | 121.15% |
Free Cash Flow | -399 | -1,752 | -1,866 | -1,074 | 535 | 2,091 |
Free Cash Flow Per Share | -28.07 | -124.54 | -132.80 | -76.43 | 37.89 | 148.62 |
Dividend Per Share | 18.000 | 34.000 | 30.000 | 27.500 | 30.000 | 27.500 |
Dividend Growth | -41.94% | 13.33% | 9.09% | -8.33% | 9.09% | 37.50% |
Gross Margin | 34.93% | 34.48% | 34.76% | 36.45% | 37.30% | 30.69% |
Operating Margin | 7.20% | 7.38% | 6.35% | 6.40% | 4.40% | 10.04% |
Profit Margin | 4.16% | 4.43% | 4.15% | 4.31% | 3.20% | 6.68% |
Free Cash Flow Margin | -1.21% | -5.37% | -6.18% | -4.20% | 2.33% | 9.35% |
EBITDA | 3,780 | 3,806 | 3,000 | 2,620 | 2,017 | 2,894 |
EBITDA Margin | 11.49% | 11.65% | 9.94% | 10.24% | 8.77% | 12.94% |
D&A For EBITDA | 1,413 | 1,396 | 1,084 | 983 | 1,005 | 648 |
EBIT | 2,367 | 2,410 | 1,916 | 1,637 | 1,012 | 2,246 |
EBIT Margin | 7.20% | 7.38% | 6.35% | 6.40% | 4.40% | 10.04% |
Effective Tax Rate | 33.68% | 33.27% | 34.80% | 28.41% | 40.28% | 30.69% |
Advertising Expenses | - | 781 | 687 | 748 | 736 | 504 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.